1 / 50

Advanced Squamous Cell Carcinoma of the Lung Is the Time Now?

Advanced Squamous Cell Carcinoma of the Lung Is the Time Now?. Program Goals. Introduction. Parsing Lung Cancer to Optimize Patient Management. Recommendations From NCCN NSCLC Guidelines. Recommendations From NCCN NSCLC Guidelines (cont).

guy-jenkins
Download Presentation

Advanced Squamous Cell Carcinoma of the Lung Is the Time Now?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advanced Squamous Cell Carcinoma of the LungIs the Time Now?

  2. Program Goals

  3. Introduction

  4. Parsing Lung Cancer to Optimize Patient Management

  5. Recommendations From NCCN NSCLC Guidelines

  6. Recommendations From NCCN NSCLC Guidelines (cont)

  7. Nab-paclitaxel vs Solvent-based Paclitaxel in First-line ChemotherapyEfficacy Results

  8. Second-line Therapy Options Are Limited in Advanced NSCLC

  9. Targetable Molecular Alterations in Nonsquamous Advanced NSCLC

  10. Potential Targetable Molecular Alterations in Advanced NSCLC, SCC

  11. SWOG S1400: Lung-MAP Study

  12. Antibody Therapy in Advanced NSCLC, Including SCC

  13. REVELStudy Design

  14. REVEL: PFS

  15. REVELForest Plot of PFS by Histologic Subgroup

  16. REVELForest Plot of OS by Histologic Subgroup

  17. REVELBleeding-related AEs

  18. Phase 3 Trials of Cetuximab in Advanced NSCLC

  19. SQUIREStudy Design

  20. SQUIREForest Plot of OS by Subgroup

  21. SQUIREExploratory Analysis of EGFR H-Score

  22. SQUIRE: AEs

  23. Role of CTLA-4 in the Immune Response

  24. Role of PD-1/PD-L1 in the Immune Response

  25. Immune System in Carcinogenesis

  26. Ipilimumab + Chemotherapy in Advanced NSCLCDesign of Phase 2 Trial

  27. Ipilimumab + Chemotherapy in Advanced NSCLCResults

  28. Ipilimumab + ChemotherapyHistology Subgroup Analysis

  29. Phase 1 Study of Nivolumab in Heavily Pretreated Pts With Advanced NSCLCHistology Subgroup Analysis

  30. Recurrent NSCLC, SCC Single-agent Nivolumab Therapy

  31. Relationship Between PD-L1 Tumor Status and Response to MK-3475Pretreated Advanced NSCLC

  32. Clinical Development of Some PD-1/PD-L1 Immune Checkpoint Inhibitors

  33. First-line MK 3475 in Advanced NSCLCStudy Design

  34. First-line MK 3475 in Advanced NSCLCEfficacy Results

  35. ASCO PerspectiveDefining Clinically Meaningful Outcomes in Lung Cancer Clinical Trials

  36. Summary: Advanced NSCLC, SCC

  37. Abbreviations

  38. Abbreviations (cont)

  39. Abbreviations (cont)

  40. References

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

  45. References (cont)

  46. References (cont)

  47. References (cont)

  48. References (cont)

More Related